Navigation Links
Chipscreen and HUYA Bioscience to Present Clinical Data on Novel HDAC Inhibitor at the 2009 ASCO Annual Meeting
Date:5/28/2009

SHENZHEN, China and SAN DIEGO, May 28 /PRNewswire/ -- Shenzhen Chipscreen Biosciences, Ltd., and HUYA Bioscience International, LLC, today announced that final data from a Phase 1 trial conducted by Chipscreen of the investigational compound chidamide (CS055/HBI-8000) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29 to June 2, 2009, in Orlando, Florida. Chidamide/HBI-8000 is a novel benzamide class histone deacetylase (HDAC) inhibitor in development by Chipscreen and HUYA for oncology indications. The data to be presented will include safety, pharmacokinetics, and biomarker and anti-tumor activity (abstract #3529).

                  Title:  "Phase 1 study of chidamide (CS055/HBI-8000), a
                          novel histone deacetylase inhibitor, in patients
                          with advanced solid tumors and lymphomas"

    Poster Presentation:  Friday, May 29, 2 pm - 6 pm EDT, Level 3, W315A,
                          Board 13

      Poster Discussion:  Friday, May 29, 5 pm - 6 pm EDT, Level 4, Valencia
                          Room, W415D

Shenzhen Chipscreen Biosciences is a leading China-based biotechnology company that specializes in discovering and developing proprietary small molecule therapeutics for unmet medical needs. The company is utilizing its proprietary chemical genomics-based discovery platform to develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas. The core competence of the company is the science-driven approach in discovery, strong pipeline building capability, experience with IP, and regulatory expertise. Additional information about the company is available at www.chipscreen.com.

HUYA Bioscience International is a leader in enabling and accelerating the global co-development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese academic and commercial biopharmaceutical organizations to enhance development efficiency and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the worldwide value of biopharmaceutical innovation in China. HUYA is jointly headquartered in San Diego, CA, and Shanghai, PRC. Additional information about the company is available at www.huyabio.com.

    Contact:
      For Chipscreen:                   For HUYA:
      Sophie Cao, M.D.                  Michael Newman, Ph.D.
      Head of Medical Affairs           Executive Vice President, Oncology
      +86 755 26719670                  +1 858 798-8800
      +86 138 23171987 mobile           +1 858 922-9015 mobile

      Zhi-Qiang Ning, M.D., Ph.D.       Juliet Travis (media contact)
      Vice President, R&D               +1 510 452-3771
      +86 755 26957727
      +86 139 24590432 mobile


'/>"/>
SOURCE HUYA Bioscience International, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017 MouthWatch LLC announced ... was ranked as the best intraoral camera on DentalCompare,s ... the #2 spot overall. The #1 product was the ... the MouthWatch intraoral camera was "…incredibly popular because it is ... camera has a small sticker price, it doesn,t sacrifice quality ...
(Date:1/23/2017)... , Jan. 23, 2017 ... U.S. devices sold and 65% increase in consumable sales, ... DarioHealth Corp. (NASDAQ: DRIO ), a leader ... developer of the Dario™ Blood Glucose Monitoring System, an ... disruptive mobile app-based and minimally invasive smart diabetes management ...
(Date:1/23/2017)...  Delcath Systems, Inc. (NASDAQ: DCTH ), ... primary and metastatic liver cancers, today announced that ... Chief Executive Officer of Delcath will be a featured ... Annual Investor Conference at the Boca Raton Resort & ... on Tuesday, January 31, 2017 at 10:30 am Eastern ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... The January 2017 issue of the Journal of ... how outdoor behavioral healthcare (OBH) – also known as wilderness therapy – helped a ... an increased sense of purpose both during and after treatment. , The study ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... ... men who support them, Dr. Carol Francis, Psychologist in the South Bay ... pay, humane respectful governing for all people and by all people shines as ...
(Date:1/23/2017)... ... January 23, 2017 , ... A Northwestern Pennsylvania addiction treatment ... Alpine Springs Rehabilitation & Recovery Center’s new website can be found at ... its redesigned and retooled website. The treatment center has also revamped its social ...
(Date:1/23/2017)... ... January 23, 2017 , ... Ultimate Medical Academy today announced ... be held March 23-25, 2017 in Tampa, and reminded educators and education leaders ... speakers include Dr. Michelle R. Weise, executive director of the Sandbox Collaborative, the ...
(Date:1/23/2017)... ... 23, 2017 , ... Wooden and plastic balance boards have been around since at least the ... Board is the first and only balance board to use a patent-pending design featuring ... at the same time as well as skill-level adjustable for all ages and abilities. ...
Breaking Medicine News(10 mins):